—
C+
C+ The full Closelooknet — membership. Open the C+ overview

UCB SA (UCB.BR) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for UCB.BR, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
Who it is priced against Biotechnology · 8 names with week and year-to-date

Peer group

Biotechnology

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against UCB.BR on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — UCB SA

UCB.BR in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
UCB is a biopharmaceutical company based in Brussels that develops medicines for neurology and immunology conditions. Its portfolio includes treatments for epilepsy, Parkinson's disease, psoriasis and related immune disorders, alongside allergy remedies and newer drugs aimed at rare neurological and autoimmune diseases. The company also carries out contract manufacturing work alongside its own drug development.
Where it sits in the stack
UCB does not hold a seat in Rubin or in Halo, the diary's build-out indices, since its business sits outside the AI hardware and software chain. It belongs instead to the Healthcare sleeve of our wider universe, grouped with other scored pharmaceutical and biotechnology names rather than with any layer of the compute stack.
Who it is priced against
Closelooknet's peer group places UCB with other scored healthcare names, including Argen-X, Eli Lilly, Medpace, BeiGene, Fisher & Paykel Healthcare, Globus Medical and Regeneron, chosen because they share the sector. A comparison the market often draws outside that list is with Novartis.
Why Closelooknet tracks it
UCB carries a Closelooknet score with quality as its strongest module and momentum as its weakest; it holds no seat in Rubin or Halo and the diary records no quotes or index mentions for it.
What the diary watches
Whether the weak momentum reading persists or turns, and whether the pipeline names now in development change the growth module that currently sits well ahead of the score's other parts.

UCB SA (UCB.BR) trades on the BR exchange in Belgium.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 0.51%, annual · last 1.03 EUR on 2026-05-04

Dividends and capital return

What UCB.BR pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 1.03 EUR per share · a 0.51% yield on the 2026-10-06 close 1 distribution, paid once a year 2026-10-06
  • Change on the year +5.5% against the prior twelve months prior twelve months 0.97 EUR per share
  • Last distribution 1.03 EUR per share as the price series records it, within days of the ex-date 2026-05-04
  • By calendar year 2025: 0.97 EUR (partial) · 2026: 1.03 EUR to date first distribution recorded in the three-year window: 2025-04-25

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is UCB SA (UCB.BR)?

UCB SA trades as UCB.BR on the BR exchange (Belgium) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is UCB.BR in a Closelooknet index?

Not currently — UCB SA is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does UCB.BR trade against its moving averages?

Downtrend stack: Trades -6% vs the 50-day and -16.8% vs the 200-day average, 29.8% below the 52-week high and +1.8% off the 52-week low; a death cross printed 41 sessions ago. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does UCB SA compare with its peers?

Against its peer group (Biotechnology), UCB SA (UCB.BR) sits 29.8% below its 52-week high, 6.0% below its 50-day average; BB Biotech AG (BION.SW) is 12.9% below, BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below. Put any of them next to UCB.BR in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

What does UCB SA do?

UCB is a biopharmaceutical company based in Brussels that develops medicines for neurology and immunology conditions. Its portfolio includes treatments for epilepsy, Parkinson's disease, psoriasis and related immune disorders, alongside allergy remedies and newer drugs aimed at rare neurological and autoimmune diseases. The company also carries out contract manufacturing work alongside its own drug development. Closelooknet's peer group places UCB with other scored healthcare names, including Argen-X, Eli Lilly, Medpace, BeiGene, Fisher & Paykel Healthcare, Globus Medical and Regeneron, chosen because they share the sector. A comparison the market often draws outside that list is with Novartis.

Where does UCB SA sit in the AI build-out?

UCB does not hold a seat in Rubin or in Halo, the diary's build-out indices, since its business sits outside the AI hardware and software chain. It belongs instead to the Healthcare sleeve of our wider universe, grouped with other scored pharmaceutical and biotechnology names rather than with any layer of the compute stack. UCB carries a Closelooknet score with quality as its strongest module and momentum as its weakest; it holds no seat in Rubin or Halo and the diary records no quotes or index mentions for it.

Does UCB SA pay a dividend?

UCB SA has paid 1.03 EUR per share over the last twelve months, paid once a year, a trailing yield of 0.51% on the 2026-10-06 close; the last distribution recorded in the price series was 1.03 EUR on 2026-05-04. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for UCB.BR, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.